GLP-1 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential
International Journal of Molecular Sciences · 05.11.2025 · 26 (21) · 10743
DOI: 10.3390/ijms262110743 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 05.11.2025. Verfasst von Osama Sobhi Moaket und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Royal College of Surgeons in Ireland-Bahrain, Busaiteen P.O. Box 15503, Bahrain. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Neurodegenerative Diseases, Brain, Neuroprotective Agents. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Neurodegenerative disorders, including Alzheimer’s disease (AD), Parkinson’s disease (PD), stroke, and depression, are marked by progressive neuronal dysfunction and loss, yet current treatments remain largely symptomatic with limited disease-modifying efficacy. Glucagon-like peptide-1 (GLP-1), an incretin hormone traditionally associated with metabolic regulation, has emerged as a promising neuroprotective agent. Its receptor, GLP-1R, is expressed in key brain regions implicated in cognition, emotion, and motor control, including the hippocampus, frontal cortex, and substantia nigra. GLP-1R agonists (GLP-1RAs) activate multiple intracellular signaling cascades—cAMP/PKA, PI3K/Akt, and MAPK pathways—that collectively promote neuronal survival, enhance synaptic plasticity, reduce oxidative stress, inhibit apoptosis, and modulate neuroinflammation. These agents also regulate autophagy, promote remyelination, and reprogram microglial phenotypes toward anti-inflammatory states. Preclinical models have shown that GLP-1RAs reduce amyloid-β and tau pathology in AD, preserve dopaminergic neurons in PD, protect astrocytes and neural progenitors after ischemic stroke, and alleviate depressive behaviors. Notably, GLP-1RAs such as liraglutide, exenatide, and dulaglutide can cross the blood–brain barrier and have demonstrated safety and potential efficacy in early-phase clinical trials. These studies report attenuation of cortical atrophy, preservation of cerebral glucose metabolism, and improvements in quality of life, though changes in core AD biomarkers remain inconclusive. Ongoing large-scale trials (e.g., EVOKE, ELAD) are further exploring their therapeutic impact. This review consolidates the mechanistic basis and translational potential of GLP-1RAs in age-related neurodegenerative diseases, highlighting both their promise and the challenges that must be addressed in future clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Royal College of Surgeons in Ireland-Bahrain, Busaiteen P.O. Box 15503, Bahrain.
- Research Department, Royal College of Surgeons in Ireland-Bahrain, Busaiteen P.O. Box 15503, Bahrain.
ORCID-Profile: Sarah Eyad Obaid, Fawaz Eyad Obaid, Yusuf Abdulkarim Shakeeb, Radwan Darwish, Alexandra E Butler, Abu Saleh Md Moin
Zitieren
APA
Moaket, O. S., Obaid, S. E., Obaid, F. E., Shakeeb, Y. A., Elsharief, S. M., Tania, A., Darwish, R., Butler, A. E., & Moin, A. S. M. (2025). GLP-1 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential. International Journal of Molecular Sciences, 26(21), 10743. https://doi.org/10.3390/ijms262110743
Vancouver
Moaket OS, Obaid SE, Obaid FE, Shakeeb YA, Elsharief SM, Tania A, et al. GLP-1 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential. International Journal of Molecular Sciences. 2025;26(21):10743. doi:10.3390/ijms262110743
BibTeX
@article{Moaket2025,
author = {Moaket, Osama Sobhi and Obaid, Sarah Eyad and Obaid, Fawaz Eyad and Shakeeb, Yusuf Abdulkarim and Elsharief, Samir Mohammed and Tania, Afrin and Darwish, Radwan and Butler, Alexandra E and Moin, Abu Saleh Md},
title = {GLP-1 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {21},
pages = {10743},
doi = {10.3390/ijms262110743}
}
EUVIMED